Live
Lupin receives final approval for its testosterone topical solution from the US health regulator.
In a BSE filing Lupin stated, “The company has received final approval for its testosterone topical solution, 30 mg per actuation from the United States Food and Drug Administration (USFDA) to market the product.”
Further it stated that, the approved solution is suggestive for replacement therapy in males for conditions which are related with deficiency or absence of endogenous testosterone.
